المؤلفون: Darío Parra, Oscar Muñoz, Diana Henao, Marisol Vergara Pinilla, Martín Rondón, Alfonso Kerguelen, Ana María Gómez

المصدر: Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Diabetes & Metabolic Syndrome

مصطلحات موضوعية: Male, TIR, Time in range, Endocrinology, Diabetes and Metabolism, MDI, Multiple Doses of Insulin, Multiple dosing, Cohort Studies, SH, severe hypoglycemia, 0302 clinical medicine, Medicine, Prospective Studies, 030212 general & internal medicine, Zoom, Prospective cohort study, TBR, Time below the range, SAP, Sensor-augmented pump therapy, Sensor-augmented pump therapy (SAPT), General Medicine, Middle Aged, Telemedicine, T1D, Type 1 Diabetes, HCL, Hybrid Closed Loop, Type 1 diabetes, TAR, Time above the range, HU, hypoglycemia unawareness, CV%, coefficient of variation, Female, Cohort study, Adult, medicine.medical_specialty, Adolescent, Coronavirus disease 2019 (COVID-19), A1c, glycosylated hemoglobin, 030209 endocrinology & metabolism, Colombia, Article, Automated insulin delivery system (AID), Young Adult, 03 medical and health sciences, Insulin Infusion Systems, Physical medicine and rehabilitation, Patient Education as Topic, Internal Medicine, Humans, Hypoglycemic Agents, Virtual training, GMI, Glucose management indicator, CGM, continuous glucose monitoring, Aged, Glycemic, business.industry, Blood Glucose Self-Monitoring, COVID-19, IQR, Interquartile range, medicine.disease, Diabetes Mellitus, Type 1, PLGM, Predictive low-glucose management, Time in range, AID, Automated insulin delivery system, business, Hybrid closed loop (HCL), Follow-Up Studies

الوصف: Background and aims In Colombia, the government established mandatory isolation after the first case of COVID-19 was reported. As a diabetes care center specialized in technology, we developed a virtual training program for patients with type 1 diabetes (T1D) who were upgrading to hybrid closed loop (HCL) system. The aim of this study is to describe the efficacy and safety outcomes of the virtual training program. Method ology: A prospective observational cohort study was performed, including patients with diagnosis of T1D previously treated with multiple doses of insulin (MDI) or sensor augmented pump therapy (SAP) who were updating to HCL system, from March to July 2020. Virtual training and follow-up were done through the Zoom video conferencing application and Medtronic Carelink System version 3.1 software. CGM data were analyzed to compare the time in range (TIR), time below range (TBR) and glycemic variability, during the first two weeks corresponding to manual mode with the final two weeks of follow-up in automatic mode. Results 91 patients were included. Mean TIR achieved with manual mode was 77.3 ± 11.3, increasing to 81.6% ± 7.6 (p
Highlights • Hybrid closed-loop (HCL) systems allows type 1 diabetes (T1D) patients to improve Time in Range (TIR). • HCL training has been delivered in person. However, during COVID-19 pandemic we had to switch to a virtual modality. • Subjects with virtual training had an increase in TIR regardless of initial therapy after two weeks of automatic use. • This is the largest prospective non-sponsored study including adults treated with HCL trained through a virtual platform.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f5881bb55526593b3ea173a4a4b845eTest
https://doi.org/10.1016/j.dsx.2020.12.041Test

المؤلفون: Fatema Abdulhussein, W. John Boscardin, Stephen E. Gitelman, Hannah Chesser, Jenise C. Wong

المصدر: Diabetes Technol Ther
Diabetes technology & therapeutics, vol 23, iss 10

مصطلحات موضوعية: Blood Glucose, Endocrinology, Diabetes and Metabolism, Medical Physiology, Pediatrics, 0302 clinical medicine, Endocrinology, Pandemic, 030212 general & internal medicine, Child, Continuous glucose monitoring, Pediatric, Diabetes, Benchmarking, Medical Laboratory Technology, Type 1 diabetes, Child, Preschool, Mandate, Type 1, Adult, medicine.medical_specialty, 2019-20 coronavirus outbreak, Adolescent, Coronavirus disease 2019 (COVID-19), Clinical Sciences, 030209 endocrinology & metabolism, Autoimmune Disease, Endocrinology & Metabolism, Young Adult, 03 medical and health sciences, Diabetes mellitus, Diabetes Mellitus, medicine, Humans, Preschool, Pandemics, Metabolic and endocrine, Retrospective Studies, Glycemic, SARS-CoV-2, business.industry, Blood Glucose Self-Monitoring, COVID-19, Original Articles, medicine.disease, Diabetes Mellitus, Type 1, Glucose, Time in range, Emergency medicine, business

الوصف: Background: The impact of the coronavirus disease-2019 (COVID-19) pandemic on glycemic metrics in children is uncertain. This study evaluates the effect of the shelter-in-place (SIP) mandate on glycemic metrics in youth with type 1 diabetes (T1D) using continuous glucose monitoring (CGM) in Northern California, United States. Methods: CGM and insulin pump metrics in youth 3-21 years old with T1D at an academic pediatric diabetes center were analyzed retrospectively. Data 2-4 months before (distant pre-SIP), 1 month before (immediate pre-SIP), 1 month after (immediate post-SIP), and 2-4 months after (distant post-SIP) the SIP mandate were compared using paired t-tests, linear regression, and longitudinal analysis using a mixed effects model. Results: Participants (n = 85) had reduced mean glucose (-10.3 ± 4.4 mg/dL, P = 0.009), standard deviation (SD) (-5.0 ± 1.3 mg/dL, P = 0.003), glucose management indicator (-0.2% ± 0.03%, P = 0.004), time above range (TAR) >250 mg/dL (-3.5% ± 1.7%, P = 0.01), and increased time in range (TIR) (+4.7% ± 1.7%, P = 0.0025) between the distant pre-SIP and distant post-SIP periods. Relationships were maintained using a mixed effects model, when controlling for other demographic variables. There was improvement in SD, TAR 180-250 mg/dL, and TIR for participants with private insurance, but changes in the opposite direction for participants with public insurance. Conclusions: Improvement in CGM metrics in youth with T1D during the COVID-19 pandemic suggests that diabetes management can be maintained in the face of sudden changes to daily living. Youth with public insurance deserve more attention in research and clinical practice.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3d77b847d3e5102aa0edc3ec801de60Test
https://doi.org/10.1089/dia.2021.0131Test

المؤلفون: Marc D. Breton, Boris Kovatchev

المصدر: Diabetes Technology & Therapeutics

مصطلحات موضوعية: Adult, Blood Glucose, Male, Insulin pump, Technology, Adolescent, Endocrinology, Diabetes and Metabolism, Automated insulin dosing, 030209 endocrinology & metabolism, Young Adult, 03 medical and health sciences, Insulin Infusion Systems, 0302 clinical medicine, Endocrinology, Control theory, Diabetes mellitus, Humans, Hypoglycemic Agents, Insulin, Medicine, 030212 general & internal medicine, Child, Continuous glucose monitoring, Retrospective Studies, business.industry, Blood Glucose Self-Monitoring, Original Articles, Middle Aged, medicine.disease, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Closed-loop control, Time in range, Female, business, Closed loop

الوصف: Background: The t:slim X2™ insulin pump with Control-IQ® technology from Tandem Diabetes Care is an advanced hybrid closed-loop system that was first commercialized in the United States in January 2020. Longitudinal glycemic outcomes associated with real-world use of this system have yet to be reported. Methods: A retrospective analysis of Control-IQ technology users who uploaded data to Tandem's t:connect® web application as of February 11, 2021 was performed. Users age ≥6 years, with >2 weeks of continuous glucose monitoring (CGM) data pre- and >12 months post-Control-IQ technology initiation were included in the analysis. Results: In total 9451 users met the inclusion criteria, 83% had type 1 diabetes, and the rest had type 2 or other forms of diabetes. The mean age was 42.6 ± 20.8 years, and 52% were female. Median percent time in automation was 94.2% [interquartile range, IQR: 90.1%–96.4%] for the entire 12-month duration of observation, with no significant changes over time. Of these users, 9010 (96.8%) had ≥75% of their CGM data available, that is, sufficient data for reliable computation of CGM-based glycemic outcomes. At baseline, median percent time in range (70–180 mg/dL) was 63.6 (IQR: 49.9%–75.6%) and increased to 73.6% (IQR: 64.4%–81.8%) for the 12 months of Control-IQ technology use with no significant changes over time. Median percent time

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6e020a803411f611cad464e7c7c1ff5Test
https://doi.org/10.1089/dia.2021.0097Test

المؤلفون: Ikumi Shigesawa, Naoki Nishimoto, Kazuno Omori, Shin Aoki, Kenichi Tsuchida, Tatsuya Atsumi, So Nagai, Shinji Taneda, Shinichiro Kawata, Hiraku Kameda, Aika Miya, Shingo Yanagiya, Akinobu Nakamura, Hiroshi Nomoto, Hideaki Miyoshi, Kyu Yong Cho, Hajime Sugawara, Kazuhisa Tsuchida, Hiroki Yokoyama, Jun Takeuchi, Yoshio Kurihara

المصدر: Journal of Diabetes Investigation, Vol 12, Iss 8, Pp 1417-1424 (2021)
Journal of Diabetes Investigation

مصطلحات موضوعية: Blood Glucose, Male, Endocrinology, Diabetes and Metabolism, 030204 cardiovascular system & hematology, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Prospective Studies, Canagliflozin, Area under the curve, SGLT2 inhibitor, General Medicine, Articles, Postprandial, Clinical Science and Care, Post-Prandial Blood Glucose, Thiazolidines, Original Article, Drug Therapy, Combination, Female, medicine.drug, Adult, medicine.medical_specialty, Combination therapy, 030209 endocrinology & metabolism, Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, Diabetes mellitus, Internal medicine, Internal Medicine, medicine, DPP-4 inhibitor, Humans, Hypoglycemic Agents, Sodium–glucose cotransporter 2inhibitor, Teneligliptin, Sodium-Glucose Transporter 2 Inhibitors, Glycemic, Dipeptidyl-Peptidase IV Inhibitors, business.industry, Glucose Tolerance Test, medicine.disease, RC648-665, Post‐prandial blood glucose, chemistry, Diabetes Mellitus, Type 2, Hyperglycemia, Time in range, Pyrazoles, Glycated hemoglobin, business

الوصف: Aims/Introduction We recently reported the beneficial effect of the combination of sodium–glucose cotransporter 2 inhibitor and dipeptidyl peptidase‐4 inhibitor on daily glycemic variability in patients with type 2 diabetes mellitus. Additional favorable effects of combination therapy were explored in this secondary analysis. Materials and Methods The CALMER study was a multicenter, open‐label, prospective, randomized, parallel‐group comparison trial for type 2 diabetes mellitus involving continuous glucose monitoring under meal tolerance tests. Patients were randomly assigned to switch from teneligliptin to canagliflozin (SWITCH group) or to add canagliflozin to teneligliptin (COMB group). The continuous glucose monitoring metrics, including time in target range, were investigated. Results All 99 participants (mean age 62.3 years; mean glycated hemoglobin 7.4%) completed the trial. The time in target range was increased in the COMB group (71.2–82.7%, P

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3760bc209d5ab90fd2836c21d04ec3e0Test
https://doaj.org/article/3e8bdc46ba6e43f5ae3287bfe8db2f38Test

المؤلفون: Jesús Moreno-Fernández, José Alberto García-Seco

المصدر: AACE Clinical Case Reports, Vol 7, Iss 3, Pp 177-179 (2021)
AACE Clinical Case Reports

مصطلحات موضوعية: TIR, time in range, TUR, time under range, Endocrinology, Diabetes and Metabolism, MM670G, Medtronic MiniMed 670G, HCL, hybrid closed-loop, Case Report, 030209 endocrinology & metabolism, Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, Hba1c level, chemistry.chemical_compound, Endocrinology, 0302 clinical medicine, Unplanned pregnancy, RT-CGM, real-time continuous glucose monitoring, Medicine, Glycated haemoglobin, Glycemic, Type 1 diabetes, Pregnancy, closed-loop, business.industry, T1DM, type 1 diabetes mellitus, General Medicine, medicine.disease, RC648-665, chemistry, 030220 oncology & carcinogenesis, Anesthesia, Glycated hemoglobin, pregnancy, HbA1c, glycated hemoglobin, business, Closed loop, type 1 diabetes mellitus

الوصف: Objective: Hybrid closed-loop (HCL) devices can achieve tight glycemic control but are rarely used in pregnancy, which remains an off-label indication. We present a case of a pregnant patient with type 1 diabetes mellitus (T1DM) who used the Medtronic MiniMed 670G HCL system. Methods: MiniMed 670G includes an advanced automode option (HCL therapy), which our patient used from the first trimester to the end of the pregnancy. Results: An unplanned pregnancy was detected in the T1DM patient, with a glycated hemoglobin level of 8.7 mmol/L (7.1%). The patient started sensor-augmented pump therapy at week 13. Subsequently, she entered automode (HCL) at week 16. The time in range (3.7-7.8 mmol/mol, 63-140 mg/dL) increased from 46.8% to 51.3% after HCL initiation. The glycated hemoglobin level remained close to 48 mmol/mol (6.5%) until the end of the pregnancy. Furthermore, the time under range (

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6feabb2e5f5e16ee0552a8fc7782826eTest
http://www.sciencedirect.com/science/article/pii/S2376060521000080Test

المؤلفون: Nunzio Camerlingo, Martina Vettoretti, Pratik Choudhary, Giovanni Sparacino, Simone Del Favero, Julia K. Mader, Andrea Facchinetti

المصدر: Diabetes, Obesity & Metabolism
Diabetes, Obesity and Metabolism

مصطلحات موضوعية: Blood Glucose, Matching (statistics), Time Factors, Cost effectiveness, clinical trial, continuous glucose monitoring, cost-effectiveness, type 1 diabetes, Blood Glucose Self-Monitoring, Humans, Diabetes Mellitus, Type 1, Endocrinology, Diabetes and Metabolism, Population, 030209 endocrinology & metabolism, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Statistics, Internal Medicine, Diabetes Mellitus, Medicine, 030212 general & internal medicine, Duration (project management), education, Reliability (statistics), education.field_of_study, Continuous glucose monitoring, business.industry, Sampling (statistics), Original Articles, cost‐effectiveness, 3. Good health, Clinical trial, time in range, Original Article, business, Type 1

الوصف: Aims Time-in-ranges, such as time-in-range (TIR), and time-in-tight-range (TITR), time-below-range (TBR), time-above-range (TAR), are key metrics to evaluate glucose control. The duration of the CGM datastream used to compute them affects their reliability: short observation periods result in uncertain estimates, while long trials grant precise evaluation but are associated with higher costs and organizational difficulties. In this paper we propose a mathematical link between the precision/uncertainty of the estimates and the number of monitoring days, that could be useful for clinicians and researchers. Materials and methods Four formulas for the above-mentioned time-in-ranges were obtained by estimating the equation's parameters on a training set extracted from study A (226 subjects, ~180 days, 5-min Dexcom G4 Platinum sensor). The formulas were then validated on the remaining data. We also illustrate how to adjust the parameters for sensors with different sampling rates. Finally, we use Study B (45 subjects, ~365 days, 15-min Abbott Freestyle Libre sensor) to further validate our results. Results Our approach was effective in predicting the uncertainty when time-in-ranges are estimated using n days of CGM, matching the variability observed in the data. As an example, monitoring a population with TIR=70%, TITR=50%, TBR=5% and TAR=25% for n=30 days warrants a precision of ±3.50%, ±3.68%, ±1.33%, ±3.66%, respectively. Conclusions The presented approach can be used both to compute the uncertainty of time-in-ranges and to determine the minimal duration of a trial to achieve a desired precision. An online tool to facilitate its implementation is made freely available to the clinical investigator. This article is protected by copyright. All rights reserved.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4001632d317abe10d96f8abe643be711Test
http://europepmc.org/articles/PMC8518626Test

المؤلفون: V. A. Peterkova, A. S. Ametov, A. Y. Mayorov, G. R. Galstyan, D. N. Laptev, N. A. Chernikova

المصدر: Сахарный диабет, Vol 24, Iss 2, Pp 185-192 (2021)

مصطلحات موضوعية: medicine.medical_specialty, RC620-627, endocrine system diseases, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, Real world evidence, law.invention, 03 medical and health sciences, chemistry.chemical_compound, flash monitoring, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Internal Medicine, medicine, In patient, Medical physics, Nutritional diseases. Deficiency diseases, intermittently scanned continues glucose monitoring, Glycemic, Continuous glucose monitoring, business.industry, Data interpretation, nutritional and metabolic diseases, Clinical Practice, chemistry, time in range, Glycated hemoglobin, business, glycated hemoglobin

الوصف: The Scientific Advisory Board chaired by Academician of the Russian Academy of Sciences, Peterkova V.A. was held 26 of November in Moscow to discuss the possibilities of continuous glucose monitoring technology (CGM) implementation into routine clinical practice in Russia in order to improve glycemic control in patients with diabetes mellitus (DM).The main aims for Advisory board were to determine the most significant indicators and parameters for CGM to be implemented in practice from a practical point of view of LMWH, necessary for implementation in clinical practice, for different patients groups with diabetes.The following questions and topics were raised within the discussion: the importance of additional indicators beyond glycated hemoglobin (HbA1c) for glycemic control assessment in diabetes patients, CGM positioning in International and Russian clinical guidelines, the accuracy of CGM devises and approaches to its assessment, the role of education programs for diabetic patients, including trainings in correct use and data interpretation and analysis of CGM data obtained, clinical evidence analysis for CGM in randomized trials and real world evidence.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27cf3c1333443ab01cea597fb49cad96Test
https://www.dia-endojournals.ru/jour/article/view/12753Test

المؤلفون: Samim Özen, Günay Demir, Yasemin Atik Altınok, Ferda Evin, Damla Gökşen, Aysun Ata, Hafize Çetin, Eren Er, Şükran Darcan

المصدر: International Journal of Diabetes in Developing Countries. 42:276-282

مصطلحات موضوعية: Risk, medicine.medical_specialty, Coefficient of variation, Multiple dose regimen, Endocrinology, Diabetes and Metabolism, Confidence, 030209 endocrinology & metabolism, Hypoglycemia, Gastroenterology, Predictive low-glucose suspend, Time, Insulin pump therapy, 03 medical and health sciences, 0302 clinical medicine, 640g, Diabetes mellitus, Internal medicine, Internal Medicine, medicine, 030212 general & internal medicine, Low glucose suspend, Glycemic variability, Reduction, Glycemic, business.industry, Range, medicine.disease, Insulin Suspension, Time in range, business

الوصف: Introduction Predictive low-glucose suspend (PLGS) system helps prevent hypoglycemia. Aim To evaluate the effect of PLGS therapy on GV and percentage of time in range (TIR), time below range (TBR), and time above range (TAR) in pediatric type 1 diabetic patients. Method HbA(1c), coefficient of variation (CV). standard deviation (SD). and percentage of TIR, TBR, and TAR were evaluated in type 1 diabetic (T1D) pediatric patients followed up between Jan 2016 and Mar 2020 using PLGS system. Results Mean ages of diagnosis and duration of diabetes were 6.7 +/- 4.1 and 8.2 +/- 4.3 years, respectively. Nineteen of the patients were male (46.3%) and 22 were female (53.7%). Twenty-two (53.7%) of the patients were using low-glucose suspend system and 19 (46.3%) were on multiple daily injection therapy (MDI). On PLGS therapy, the 3rd, 6th, 9th, and 12th months' HbA(1c) of patients were not different from previous years' mean HbA(1c) in all participants. In the 3rd, 6th, 9th, and 12th months of PLGS therapy, % of TIR were 65.34 +/- 14.75%, 65.80 +/- 14.67%, 66.58 +/- 11.21%, and 70.04 +/- 10.16%, respectively (p = 0.01). Although statistically insignificant, CV decreased from 36.33 to 34.30% and SD decreased from 60.14 to 58.60 in the 1-year follow-up period (p = 0.062 and p = 0.246). Conclusion With PLGS therapy, TIR was > 70% and the time spent in hypoglycemia was very low.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de1c98ce379a77a613b27df3743d4053Test
https://doi.org/10.1007/s13410-021-00957-1Test

المؤلفون: Mitsuyoshi Namba, Taku Tsunoda, Satoshi Matsutani, Tomoyuki Katsuno, Yoshiki Kusunoki, Mana Ohigashi, Kahori Washio, Toshihiro Matsuo, Hidenori Koyama, Keiko Osugi, Kosuke Konishi

المصدر: Journal of Diabetes Investigation, Vol 12, Iss 6, Pp 940-949 (2021)
Journal of Diabetes Investigation

مصطلحات موضوعية: Glycation End Products, Advanced, Male, Time Factors, endocrine system diseases, Endocrinology, Diabetes and Metabolism, 030204 cardiovascular system & hematology, Gastroenterology, Impaired glucose tolerance, 0302 clinical medicine, Glycated albumin, Glycated Serum Albumin, Continuous glucose monitoring, Articles, General Medicine, Middle Aged, Clinical Science and Care, Original Article, Female, Adult, medicine.medical_specialty, 030209 endocrinology & metabolism, Glycemic Control, Deoxyglucose, Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, Diabetes mellitus, Internal medicine, Glucose Intolerance, Internal Medicine, medicine, Humans, Serum Albumin, Aged, Glucose Metabolism Disorders, Retrospective Studies, Glycemic, Glycated Hemoglobin, Type 1 diabetes, business.industry, Blood Glucose Self-Monitoring, Type 2 Diabetes Mellitus, nutritional and metabolic diseases, medicine.disease, RC648-665, Confidence interval, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hemoglobin A1c, Time in range, Hemoglobin, business

الوصف: Aims/Introduction Hemoglobin A1c (HbA1c), glycated albumin (GA) and 1,5‐anhydro‐d‐glucitol (1,5‐AG) are used as indicators of glycemic control, whereas continuous glucose monitoring (CGM) is used to assess daily glucose profiles. The aim of this study was to investigate the relationships between CGM metrics, such as time in range (TIR), and glycemic control indicators. Materials and Methods We carried out retrospective CGM and blood tests on 189 outpatients with impaired glucose tolerance (n = 22), type 1 diabetes mellitus (n = 67) or type 2 diabetes mellitus (n = 100). Results In type 1 diabetes mellitus and type 2 diabetes mellitus patients, HbA1c and GA were negatively correlated with TIR, whereas 1,5‐AG was positively correlated with TIR. In type 1 diabetes mellitus patients, a TIR of 70% corresponded to HbA1c, GA and 1,5‐AG of 6.9% (95% confidence interval [CI] 6.5–7.2%), 20.3% (95% CI 19.0–21.7%) and 6.0 µg/mL (95% CI 5.1–6.9 µg/mL), respectively. In type 2 diabetes mellitus patients, a TIR of 70% corresponded to HbA1c, GA and 1,5‐AG of 7.1% (95% CI 7.0–7.3%), 19.3% (95% CI 18.7–19.9%) and 10.0 µg/mL (95% CI 9.0–11.0 µg/mL), respectively. TIR values corresponding to HbA1c levels of 7.0% were 56.1% (95% CI 52.3–59.8%) and 74.2% (95% CI 71.3–77.2%) in type 1 diabetes mellitus and type 2 diabetes mellitus patients, respectively. Conclusions The results of this study showed that the estimated HbA1c corresponding to a TIR of 70% was approximately 7.0% for both type 1 diabetes mellitus and type 2 diabetes mellitus patients, and that the estimated 1,5‐AG calculated from the TIR of 70% might be different between type 1 diabetes mellitus and type 2 diabetes mellitus patients.
Hemoglobin A1c was the most useful explanatory factor for mean sensor glucose levels. Glycated albumin was the most useful explanatory factor for glycemic variability and time in range.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa45063b321f25b0e0ca8df59292d0e2Test
https://doaj.org/article/42e2910c951147b39295cfca44d7ff10Test

المؤلفون: Anke Wesselius, Annemarie Koster, Simone J. P. M. Eussen, Pieter C. Dagnelie, Ronald M.A. Henry, Carla J.H. van der Kallen, Yuri D. Foreman, Martijn C. G. J. Brouwers, Coen D.A. Stehouwer, Miranda T. Schram, Abraham A. Kroon, Nicolaas C. Schaper, Koen D. Reesink, Marleen M.J. van Greevenbroek, William P. T. M. van Doorn

المساهمون: RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, Interne Geneeskunde, RS: Carim - B01 Blood proteins & engineering, MUMC+: DA CDL Algemeen (9), RS: CAPHRI - R2 - Creating Value-Based Health Care, RS: Carim - V02 Hypertension and target organ damage, MUMC+: HVC Pieken Maastricht Studie (9), Sociale Geneeskunde, RS: CAPHRI - R4 - Health Inequities and Societal Participation, Epidemiologie, Complexe Genetica, RS: NUTRIM - R3 - Respiratory & Age-related Health, Biomedische Technologie, RS: Carim - H07 Cardiovascular System Dynamics, MUMC+: MA Alg Interne Geneeskunde (9), MUMC+: MA Endocrinologie (9), MUMC+: Centrum voor Chronische Zieken (3), MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), MUMC+: MA Interne Geneeskunde (3)

المصدر: Diabetologia, 64(8), 1880-1892. Springer, Cham
Diabetologia

مصطلحات موضوعية: Blood Glucose, Male, Time Factors, Endocrinology, Diabetes and Metabolism, Blood Pressure, Type 2 diabetes, 030204 cardiovascular system & hematology, 0302 clinical medicine, Continuous glucosemonitoring, Prospective Studies, OXIDATIVE STRESS, Prospective cohort study, Continuous glucose monitoring, Pulse wave velocity, ALL-CAUSE MORTALITY, education.field_of_study, CARDIOVASCULAR RISK, Middle Aged, Arterial stiffness, Carotid Arteries, Cohort, Cardiology, Female, Aortic stiffness, medicine.medical_specialty, Population, 030209 endocrinology & metabolism, Pulse Wave Analysis, Risk Assessment, Article, COGNITIVE PERFORMANCE, MECHANISMS, Prediabetic State, 03 medical and health sciences, Vascular Stiffness, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, education, Aged, GLYCEMIC VARIABILITY, business.industry, Blood Glucose Self-Monitoring, Glucose variability, medicine.disease, INDIVIDUALS, Cross-Sectional Studies, Diabetes Mellitus, Type 2, MYOCARDIAL-INFARCTION, Time in range, DIABETIC COMPLICATIONS, business, Diabetic Angiopathies

الوصف: Aims CVD is the main cause of morbidity and mortality in individuals with diabetes. It is currently unclear whether daily glucose variability contributes to CVD. Therefore, we investigated whether glucose variability is associated with arterial measures that are considered important in CVD pathogenesis. Methods We included participants of The Maastricht Study, an observational population-based cohort, who underwent at least 48 h of continuous glucose monitoring (CGM) (n = 853; age: 59.9 ± 8.6 years; 49% women, 23% type 2 diabetes). We studied the cross-sectional associations of two glucose variability indices (CGM-assessed SD [SDCGM] and CGM-assessed CV [CVCGM]) and time in range (TIRCGM) with carotid–femoral pulse wave velocity (cf-PWV), carotid distensibility coefficient, carotid intima–media thickness, ankle–brachial index and circumferential wall stress via multiple linear regression. Results Higher SDCGM was associated with higher cf-PWV after adjusting for demographics, cardiovascular risk factors and lifestyle factors (regression coefficient [B] per 1 mmol/l SDCGM [and corresponding 95% CI]: 0.413 m/s [0.147, 0.679], p = 0.002). In the model additionally adjusted for CGM-assessed mean sensor glucose (MSGCGM), SDCGM and MSGCGM contributed similarly to cf-PWV (respective standardised regression coefficients [st.βs] and 95% CIs of 0.065 [−0.018, 0.167], p = 0.160; and 0.059 [−0.043, 0.164], p = 0.272). In the fully adjusted models, both higher CVCGM (B [95% CI] per 10% CVCGM: 0.303 m/s [0.046, 0.559], p = 0.021) and lower TIRCGM (B [95% CI] per 10% TIRCGM: −0.145 m/s [−0.252, −0.038] p = 0.008) were statistically significantly associated with higher cf-PWV. Such consistent associations were not observed for the other arterial measures. Conclusions Our findings show that greater daily glucose variability and lower TIRCGM are associated with greater aortic stiffness (cf-PWV) but not with other arterial measures. If corroborated in prospective studies, these results support the development of therapeutic agents that target both daily glucose variability and TIRCGM to prevent CVD. Graphical abstract

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75984c1c6e0ce4ecdbf1c98cc55ed434Test
https://doi.org/10.1007/s00125-021-05474-8Test